PP
RPTX

PDT Partners’s Repare Therapeutics RPTX Stock Holding History

PDT Partners’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,038
Closed -$99.1K – 806
2024
Q2 		$99.1K Sell
30,038
-42
-0.1% -$150 0.01% 640
2024
Q1 		$142K Buy
+30,080
New +$193K 0.01% 598

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PDT Partners's RPTX Position: Q3 2024 in Review

PDT Partners sold out of Repare Therapeutics (RPTX) in Q3 2024, closing a stake of 30,038 shares — an estimated $99.1K sold.

PDT Partners first reported a position in RPTX in Q1 2024 and held it in 2 quarters. The position peaked at $142K in Q1 2024. 56 funds tracked by Wall St. Rank hold RPTX as of Q3 2024.

  • PDT Partners reported no remaining Repare Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 30,038 Repare Therapeutics shares in Q3 2024, an estimated $99.1K.
  • PDT Partners first reported a position in Repare Therapeutics in Q1 2024 and held it in 2 quarters.
  • PDT Partners's Repare Therapeutics position peaked at $142K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.